Engineered immune cells take aim at stubborn cancers

NCT ID NCT03190941

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell activity. The goal is to see if this treatment can shrink tumors in adults with pancreatic, gastric, colon, or rectal cancers that have this mutation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically modified immune cells (anti-KRAS G12V mTCR cells)
What this could lead to: If it works, this could offer a new treatment option for people with certain hard-to-treat cancers that have the KRAS G12V mutation.
What could go wrong: This is an early-phase trial with only 110 participants, so it may not work for everyone. The chemotherapy and cell infusion can cause serious side effects like low blood counts and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer digestive system cancer digestive system neoplasm gastric cancer gastric neoplasm malignant pancreatic neoplasm non-small cell lung carcinoma ovarian cancer pancreatic neoplasm prostate cancer rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER GASTRIC CANCER GASTROINTESTINAL CANCER PANCREATIC CANCER RECTAL CANCER

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.